Hatteras Venture Partners

Hatteras’ mission is to build transformational human medicine companies that benefit patients and the professionals who serve them

A preclinical-stage start-up focused on developing a versatile epigenetic editing platform that uses multiple effectors for a variety of applications

Developing an extracardiac, extravascular approach to cardiac pacing and defibrillation

Iris delivers improved health outcomes, member experience and cost savings to your plan with our intuitive and customizable Advance Care Planning solutions

A clinical-stage AAV gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness

Developing engineered viral vectors for gene therapy using structure-inspired design of adeno-aden-associated virus (AAV) vectors that can evade neutralizing antibodies, a current limitation of existing gene therapies

A clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology

Providing on-demand clinical research infrastructure to enable large physician practices to offer clinical trial participation to their clients

Developing small molecules that target functional 3D RNA structures to treat human disease

Developing an integrated embolic protection platform to improve the safety and efficacy of catheter-based interventions

Developing a new standard in the surgical treatment of obesity